ATWLPPR Peptide TFA, a heptapeptide, acts as a selectiveneuropilin-1inhibitor, inhibitsVEGF₁₆₅binding to NRP-1, used in the research of angiogenesis^[1]. ATWLPPR Peptide TFA has potential in reducing the early retinal damage caused by diabetes^[2].

Neuropilin-1^[2]

ATWLPPR Peptide TFA is a selective neuropilin-1 inhibitor, inhibits VEGF₁₆₅binding to NRP-1 by 82% at 100 μM^[1].

ATWLPPR (400 μg/kg, s.c.) preserves vascular integrity and decreases the oxidative stress level, possibly reduces the early retinal damage caused by diabetes^[2].
ATWLPPR prevents the increase of inflammation-associated proteins (GFAP, VEGF and ICAM-1) in the retina^[2].

954.00

Solid

C₄₂H₆₂F₃N₁₁O₁₁

Room temperature in continental US; may vary elsewhere.

Sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

H₂O : ≥ 50 mg/mL(52.41 mM)

*"≥" means soluble, but saturation unknown.

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture and light)。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

• 1.

  请依序添加每种溶剂： PBS

  Solubility: 100 mg/mL (104.82 mM); Clear solution; Need ultrasonic